Is renal denervation a natural antihypertensive treatment?

Affiliations

Editorial

Masaki Mogi. Hypertens Res. 2023 Jan.

. 2023 Jan;46(1):289-290.

doi: 10.1038/s41440-022-01109-6. Epub 2022 Nov 15.

¹ Department of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, 791-0295, Japan. mmogi@m.ehime-u.ac.jp.

No abstract available

Comment on

Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.
Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Brar S, Hettrick DA, Fahy M, Böhm M. Kario K, et al. Hypertens Res. 2023 Jan;46(1):280-288. doi: 10.1038/s41440-022-01042-8. Epub 2022 Oct 15. Hypertens Res. 2023. PMID: 36241705 Free PMC article. Clinical Trial.

1. Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2022. (in press). https://doi.org/10.1038/s41440-022-01042-8
1. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022;399:1401–10. - DOI
1. de la Sierra A, Pareja J, Armario P, Barrera A, Yun S, Vázquez S, et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. Am J Hypertens. 2017;30:37–41. - DOI
1. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–55. - DOI
1. Peters R, Xu Y, Eramudugolla R, Sachdev PS, Cherbuin N, Tully PJ, et al. Diastolic blood pressure variability in later life may be a key risk marker for cognitive decline. Hypertension 2022;79:1037–44. - DOI